dr. penson on the eligibility criteria for parp inhibitors in advanced ovarian cancer
Published 4 years ago • 68 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
1:30
dr. penson on research with parp inhibitors in ovarian cancer
-
1:26
dr. penson on biomarkers of response to parp inhibitors in ovarian cancer
-
0:42
dr. penson on re-challenging with parp inhibition in ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
1:48
dr. penson on olaparib monotherapy vs chemo for ovarian cancer
-
6:43
sequencing parp inhibitors in advanced ovarian cancer
-
0:50
dr. secord on the role of parp inhibitors in ovarian cancer
-
3:44
the future role of parp inhibition in ovarian cancer
-
1:22
dr. gunderson on the use of parp inhibitors in all-comers with ovarian cancer
-
39:03
the therapeutic potential of novel parp inhibitors in the clinic for epithelial ovarian cancer
-
0:58
dr. o’malley on the optimal use of parp inhibitors in advanced ovarian cancer
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
5:34
differences among parp inhibitors in ovarian cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
1:08
dr. essel on repeat use of parp inhibitors in ovarian cancer
-
1:09
dr. zakashansky on repeat exposure to parp inhibitors in patients with ovarian cancer
-
0:47
dr. richards on parp inhibition in pancreatic cancer
-
0:59
dr. slamon on parp inhibitors in ovarian cancer
-
2:06
dr. konecny discusses the role of parp inhibitors in ovarian cancer